ERBB2 and breast carcinoma: Through extensive structure-activity relationship (SAR) studies on these indazole surrogates, we have synthesized a novel C-terminal HSP90 inhibitor, HVH-2930, a promising candidate for the treatment of HER2-positive breast cancer (Figure 1).